194 related articles for article (PubMed ID: 37199488)
1. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component.
Jauhiainen S; Ilmonen H; Vuola P; Rasinkangas H; Pulkkinen HH; Keränen S; Kiema M; Liikkanen JJ; Laham-Karam N; Laidinen S; Beter M; Aavik E; Lappalainen K; Lohi J; Aronniemi J; Örd T; Kaikkonen MU; Salminen P; Tukiainen E; Ylä-Herttuala S; Laakkonen JP
Elife; 2023 May; 12():. PubMed ID: 37199488
[TBL] [Abstract][Full Text] [Related]
2. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
3. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
[TBL] [Abstract][Full Text] [Related]
5. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
6. A Xenograft Model for Venous Malformation.
Goines J; Boscolo E
Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818
[TBL] [Abstract][Full Text] [Related]
7. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
[TBL] [Abstract][Full Text] [Related]
8. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
9. A Patient-Derived Xenograft Model for Venous Malformation.
Schrenk S; Goines J; Boscolo E
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867
[TBL] [Abstract][Full Text] [Related]
10. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
11. Genetic landscape of common venous malformations in the head and neck.
Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA
J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299
[TBL] [Abstract][Full Text] [Related]
12. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
[TBL] [Abstract][Full Text] [Related]
13. Shear stress and pathophysiological PI3K involvement in vascular malformations.
Abdelilah-Seyfried S; Ola R
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747293
[TBL] [Abstract][Full Text] [Related]
14. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
Martinez-Corral I; Zhang Y; Petkova M; Ortsäter H; Sjöberg S; Castillo SD; Brouillard P; Libbrecht L; Saur D; Graupera M; Alitalo K; Boon L; Vikkula M; Mäkinen T
Nat Commun; 2020 Jun; 11(1):2869. PubMed ID: 32513927
[TBL] [Abstract][Full Text] [Related]
15. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
16. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutations in vascular malformations.
Castillo SD; Baselga E; Graupera M
Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
[TBL] [Abstract][Full Text] [Related]
18. Venous malformations: PIK3CA mutations guide new treatments.
Dbouk HA
Oncotarget; 2016 Aug; 7(31):48852-48853. PubMed ID: 27447853
[No Abstract] [Full Text] [Related]
19. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]